Targeting a tumor-specific laminin domain critical for human carcinogenesis

Mark Tran1, Patricia Rousselle, Pasi Nokelainen

  • 1Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Cancer Research
|April 17, 2008
PubMed

Insights

The G45 fragment of laminin-332, absent in normal tissues but present in squamous cell carcinoma (SCC) tumors, drives SCC tumorigenesis. Targeting G45 selectively inhibits SCC growth without harming healthy tissues, offering a novel cancer therapy approach.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Laminin-332 is crucial for squamous cell carcinoma (SCC) development.
  • Targeting laminin-332 for cancer therapy is challenging due to its role in tissue integrity.

Purpose of the Study:

  • To investigate the specific role of the G45 fragment of laminin-332 in human SCC tumorigenesis.
  • To evaluate G45 as a potential therapeutic target for SCC.

Main Methods:

  • Generated human keratinocytes lacking the G45 domain (DeltaG45).
  • Analyzed cellular behavior, signaling pathways (ERK, PI3K), and matrix metalloproteinase activity in DeltaG45 cells.
  • Assessed the in vivo tumorigenicity of DeltaG45 cells and the effects of G45 antibody treatment on SCC tumors.

Main Results:

  • The G45 fragment is prominently expressed in human SCC tumors but absent in normal tissues.
  • DeltaG45 keratinocytes exhibited altered receptor organization, impaired matrix deposition, and increased migration.
  • Absence of G45 in SCC cells led to deficient PI3K/ERK pathway activation, impaired invasion, reduced metalloproteinase activity, and loss of tumorigenicity.
  • G45 expression or PI3K activation restored normal cellular functions in DeltaG45 cells.
  • G45 antibody treatment induced SCC apoptosis, reduced proliferation, and inhibited tumor growth in vivo without affecting normal tissue adhesion.

Conclusions:

  • The laminin-332 G45 fragment displays selective expression and function in human SCC tumorigenesis.
  • G45 is a specific and promising therapeutic target for squamous cell carcinoma treatment.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Laminins are the Adhesive Proteins of Basal Lamina00:55

Laminins are the Adhesive Proteins of Basal Lamina

Laminins are heterotrimeric proteins with high molecular mass found in the extracellular matrix. Each laminin molecule is composed of three chains, viz. alpha, beta, and gamma, coded by five, four, and three paralogous genes, respectively. Laminins are categories based on the compositions of the three chains.
In humans, the five forms of alpha chains are LAMA 1, LAMA 2, LAMA 3, LAMA 4, and LAMA 5. The four forms of beta chains are LAMB 1, LAMB 2, LAMB 3, and LAMB 4. The three forms of gamma...